Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Crinetics Pharmaceuticals was $591.25 million, up 39.3% year-over-year; for FY2025, it was $524.47 million, up 54.3% from FY2024.

• Annual Operating Expenses has increased for nine consecutive years, with a five-year compound annual growth rate of 47.5% (FY2020 to FY2025).
• In prior years, Crinetics Pharmaceuticals' Operating Expenses was $339.89 million in FY2024 (+50.0%), $226.62 million in FY2023 (+31.3%), $172.62 million in FY2022 (+58.7%) and $108.78 million in FY2021 (+45.0%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q2 2017.
• On a year-over-year basis, Operating Expenses has increased in each of the last 33 quarters, with growth averaging 46.6% over the last eight quarters.
• Across the past five years, year-over-year growth in Operating Expenses ran from 21.1% in Q2 2026 to 66.7% in Q2 2022.
• According to Business Quant data, Operating Expenses for the three prior quarters was $151.11 million (Q1 2026), $139.83 million (Q4 2025) and $142.73 million (Q3 2025).